FLUORINE-CONTAINING 5-[2-(PYRID-3-YL)-ETHYL]-2,3,4-TETRAHYDRO-1 -PYRIDO[4,3-B]INDOLES AS AGENTS FOR REDUCING UNCONTROLLED PROTEIN AGGREGATION

The claimed fluorine-containing substituted 5-[2-(pyrid-3-yl)-ethyl]-2,3,4-tetrahydro-1H-pyrido[4,3-b]indoles and hydrochlorides and hydrobromides thereof, which have the general formula (I), as agents for reducing uncontrolled protein aggregation in the nervous system, the pharmacological agent based thereon and the method for using same relate to the field of medicine and solve the problem of increasing the range of agents for combating the development of destructive processes in the central and peripheral nervous system. Formula (I), where R1 = R2 = R4 = , Me; or R4 + R2 = -C 2-C 2-; R3 = , (C1-C6) alkyl, (C2-C6) alkenyl, (C -C6) alkynyl, (C1-C6) alkoxy (C1-C6) alkyl, [F, Cl, Br, NO2, (C1-C6) alkyl, (C1-C6) alkoxy, acyl, (C1-C6) alkylsulfonyl, (C1- C6) alkoxycarbonyl - substituted] aryloxy (C1-C6) alkyl, (C3-C7) cycloalkyl, [F, Cl, r, NO2, (C1-C6) alkyl, (C1-C6) alkoxy, acyl, (C1-C6) alkylsulfonyl, (C1-C6) alkoxycarbonyl - substituted] aryl, heteryl, (C1-C6) alkylsulfonyl, (C1-C6) alkoxycarbonyl, (C1-C6) acyl, [F, Cl, Br, NO2, (C1-C6) alkyl, (C1-C6) alkoxy, acyl, (C1- C6) alkylsulfonyl, (C1-C6) alkoxycarbonyl - substituted] aroyl, heteroyl, Nu,Nu-dialkylcarbamoyl, Nu,Nu-dialkylaminosulfonyl; R5, R6, R7, R8 = H, F, Cl, Br, CN, OH, CF3, CF3O, CHF2O, NO2, (C1-C6) alkyl, (C3-C7) cycloalkyl, (C1-C6) alkoxy, [F, Cl, Br, NO2, (C1-C6) alkyl, (C1-C6) alkoxy, acyl, (C1-C6) alkylsulfonyl, (C1-C6) alkoxycarbonyl - substituted] aryl, [F, Cl, Br, NO2, (C1-C6) alkyl, (C1-C6) alkoxy, acyl, (C1-C6) alkylsulfonyl, (C1-C6) alkoxycarbonyl - substituted] aryloxy, (Me, Cl, Br - substituted) pyridyl, (C1-C6) alkylsulfonyl, (C1- C6) alkoxycarbonyl, (C1-C6) acyl, [F, Cl, Br, NO2, (C1-C6) alkyl, (C1-C6) alkoxy, acyl, (C1-C6) alkylsulfonyl, (C1-C6) alkoxycarbonyl - substituted] aroyl, Nu,Nu-dialkylcarbamoyl, Nu,Nu-dialkylaminosulfonyl; R9 = F, 2F, CHF2, CC1F2, CF3.; X = nothing, Cl. Br. L'invention concerne des 5-[2-(pyrid-3-yl)-éthyl]-2,3,4-tétrahydro-1H-pyrido[4,3-b]indoles fluorés substitués, leurs hydrochlorures et hydrobromures de la formule générale (1) utilisés en tant que moyen de réduction d'une agrégation protéique incontrôlée dans le système nerveux, une préparation pharmacologique sur leur base et leur procédé d'utilisation qui se rapportent au domaine de la médecine et permettent d'élargir la gamme des moyens entrainant le développement de processus destructeurs dans les systèmes nerveux central et périphérique. Formule (I), dans laquelle R1 = R2 = R4 = , Me; ou R4 +